The Anti-Cancer Potency and Mechanism of a Novel Tumor-Activated Fused Toxin, DLM
Open Access
Abstract
Melittin, which acts as a membrane-disrupting lytic peptide, is not only cytotoxic to tumors, but also vital to normal cells. Melittin had low toxicity when coupled with target peptides. Despite significant research development with the fused toxin, a new fused toxin is needed which has a cleavable linker such that the fused toxin can release melittin after protease cleavage on the tumor cell surface. We describe a novel fused toxin, composed of disintegrin, uPA (urokinase-type plasminogen activator)-cleavable linker, and melittin. Disintegrin is a single strand peptide (73 aa) isolated from Gloydius Ussuriensis venom. The RGD (Arg-Gly-Asp) site of disintegrin dominates its interaction with integrins on the surface of the tumor cells. uPA is over-expressed and plays an important role in tumor cell invasiveness and metastatic progression. The DLM (disintegrin-linker-melittin) linker is uPA-cleavable, enabling DLM to release melittin. We compared binding activity of our synthesized disintegrin with native disintegrin and report that DLM had less binding activity than the native form. uPA-cleavage was evaluated in vitro and the uPA-cleavable linker released melittin. Treating tumors expressing uPA with DLM enhanced tumor cell killing as well as reduced toxicity to erythrocytes and other non-cancerous normal cells. The mechanism behind DLM tumor cell killing was tested using a DNA ladder assay, fluorescent microscopy, flow cytometry, and transmission electron microscopy. Data revealed tumor cell necrosis as the mechanism of cell death, and the fused DLM toxin with an uPA-cleavable linker enhanced tumor selectivity and killing ability.Keywords
This publication has 38 references indexed in Scilit:
- Multiple Membrane Interactions and Versatile Vesicle Deformations Elicited by MelittinToxins, 2013
- Therapeutic potential of snake venom in cancer therapy: current perspectivesAsian Pacific Journal of Tropical Biomedicine, 2013
- Tumor-Targeting Drug Delivery of New-Generation TaxoidsFuture Medicinal Chemistry, 2011
- Snake Venom Disintegrins and Cell MigrationToxins, 2010
- Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growthJournal of Clinical Investigation, 2009
- Trafficking and Cell MigrationTraffic, 2009
- Mechanism and kinetics of pore formation in membranes by water-soluble amphipathic peptidesProceedings of the National Academy of Sciences, 2008
- How to develop a successful cancer drug – molecules to medicines or targets to treatments?European Journal of Cancer, 2005
- Sensing the environment: a historical perspective on integrin signal transductionNature Cell Biology, 2002
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990